12 Best Healthcare Stocks to Buy According to Analysts

7) Moderna, Inc. (NASDAQ:MRNA)

Number of Hedge Fund Holders: 34

Average Upside Potential: 72.6%

Moderna, Inc. (NASDAQ:MRNA) is a biotechnology company, which is engaged in discovering, developing, and commercializing messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases.  Moderna, Inc. (NASDAQ:MRNA)’s shares came under the investors’ radar after Oracle Chairman Larry Ellison discussed the transformative potential of AI in healthcare during a meeting at the White House. Ellison highlighted that AI can revolutionize cancer detection, treatment, and vaccine development, resulting in groundbreaking capabilities.

Ellison also claimed that through the use of AI, a messenger RNA-based vaccine can be produced robotically in just 48 hours. Notably, Moderna, Inc. (NASDAQ:MRNA) is utilizing its mRNA technology to develop a cancer vaccine in partnership with Merck. Furthermore, the success of cancer vaccines provides a transformative opportunity for Moderna, Inc. (NASDAQ:MRNA). The company’s diverse pipeline, spanning respiratory vaccines, cancer therapeutics, and rare disease treatments, is expected to result in significant long-term revenue potential.

The mRNA platform’s versatility enables for rapid development and adaptation of new therapies, catering to a wide range of medical needs. Moderna, Inc. (NASDAQ:MRNA) operates as a tech-driven platform, using its innovative mRNA technology to ramp up drug development, scale production, and achieve increased margins.